Studienüberblick zur Frühgeborenenretinopathie

Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity

(2018) Andreas Stahl et al.   JAMA Pediatrics

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity

(2017) David K. Wallace et al.   JAMA Ophthalmology

Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab

(2017) Amir R. Hajrasouliha et al.   Ophthalmic Surgery Lasers & Imaging Retina

The German ROP Registry: data from 90 infants treated for retinopathy of prematurity

(2016) Johanna M. Walz et al.   ACTA OPHTHALMOLOGICA

Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity

(2016) J. Morin et al.   PEDIATRICS

Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis

(2016) Simona D. Nicoară et al.   MEDICAL SCIENCE MONITOR

Current Practice Patterns for Treatment of Retinopathy of Prematurity

(2016) Kirstin L. Tawse et al.   Ophthalmic Surgery Lasers & Imaging Retina

Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab

(2016) Laura L. Snyder et al.   Ophthalmic Surgery Lasers & Imaging Retina

Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment

(2016) Reyin Lien et al.   PLoS One

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

(2015) Murat Gunay et al.   ARQUIVOS BRASILEIROS DE OFTALMOLOGIA

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

(2015) Ying Zhou et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity

(2015) Christopher K. Hwang et al.   OPHTHALMOLOGY

PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION

(2015) Yoo Rha Hong et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment

(2014) Megan M. Geloneck et al.   JAMA Ophthalmology

Intravitreal low-dosage bevacizumab for retinopathy of prematurity

(2013) Björn C. Harder et al.   ACTA OPHTHALMOLOGICA

Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab

(2013) Shaun Ittiara et al.   JOURNAL OF AAPOS

Pharmakokinetik intravitreal applizierter VEGF-Inhibitoren

(2013) T.U. Krohne et al.   OPHTHALMOLOGE

Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity

(2011) Tatsuhiko Sato et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

(2011) Helen A. Mintz-Hittner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

(2010) K. Matsuyama et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Leitlinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen

(2009) C. Jandeck et al.   OPHTHALMOLOGE

Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control

(2008) Clare Gilbert   EARLY HUMAN DEVELOPMENT